Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

Arturo Vega-Ruiz, Susan O'Brien, Jorge Cortes, Partow Kebriaei, Deborah Thomas, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.

Original languageEnglish (US)
Pages (from-to)1468-1471
Number of pages4
JournalLeukemia Research
Volume32
Issue number9
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics
Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Central Nervous System
Imatinib Mesylate
Recurrence
Drug Therapy

Keywords

  • Imatinib mesylate
  • Myelodysplastic syndrome
  • Philadelphia-positive acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. / Vega-Ruiz, Arturo; O'Brien, Susan; Cortes, Jorge; Kebriaei, Partow; Thomas, Deborah; Kantarjian, Hagop; Ravandi, Farhad.

In: Leukemia Research, Vol. 32, No. 9, 01.09.2008, p. 1468-1471.

Research output: Contribution to journalArticle

Vega-Ruiz, Arturo ; O'Brien, Susan ; Cortes, Jorge ; Kebriaei, Partow ; Thomas, Deborah ; Kantarjian, Hagop ; Ravandi, Farhad. / Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. In: Leukemia Research. 2008 ; Vol. 32, No. 9. pp. 1468-1471.
@article{d6d2e133335a4f38b4760f9391187481,
title = "Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate",
abstract = "The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.",
keywords = "Imatinib mesylate, Myelodysplastic syndrome, Philadelphia-positive acute lymphoblastic leukemia",
author = "Arturo Vega-Ruiz and Susan O'Brien and Jorge Cortes and Partow Kebriaei and Deborah Thomas and Hagop Kantarjian and Farhad Ravandi",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2008.02.001",
language = "English (US)",
volume = "32",
pages = "1468--1471",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

AU - Vega-Ruiz, Arturo

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Kebriaei, Partow

AU - Thomas, Deborah

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.

AB - The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.

KW - Imatinib mesylate

KW - Myelodysplastic syndrome

KW - Philadelphia-positive acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=43049165812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049165812&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.02.001

DO - 10.1016/j.leukres.2008.02.001

M3 - Article

C2 - 18355919

AN - SCOPUS:43049165812

VL - 32

SP - 1468

EP - 1471

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -